Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Kidney Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Magnetic Resonance Spectroscopy 9pembrolizumab 7Specimen Handling 7Biopsy 7Leucovorin 5Gemcitabine 5Cisplatin 5durvalumab 4Oxaliplatin 4Fluorouracil 4Capecitabine 4Paclitaxel 3Nivolumab 3Irinotecan 3Carboplatin 3tislelizumab 2olaparib 2fludarabine 2atezolizumab 2Trastuzumab 2Taxes 2Radiation Dose Hypofractionation 2Radiation 2Ipilimumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2zimberelimab 1varlilumab 1tucatinib 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Cholangiocarcinoma × guadecitabine × Clear all
NCT03257761 2026-06-01

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

University of Southern California

Phase 1 Active not recruiting
55 enrolled
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡